WebMar 6, 2024 · IRVINE, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced positive results from the FLAME study in high-risk/massive pulmonary embolism (“PE”). WebDec 21, 2024 · The Flow Triever System by Inari Medical is one of the two catheter based systems that received FDA approval specific to PE treatment in attempt to offer safer bleeding profile without offsetting the efficacy. ... This was already tested in earlier published retrospective study by Toma al, where 34 patients with high-intermediate and high-risk ...
Lisa Mae Dominia - Marketing Manager - Inari Medical LinkedIn
WebMar 12, 2024 · FLowTriever for Acute Massive Pulmonary Embolism (FLAME) Actual Study Start Date : March 16, 2024. Actual Primary Completion Date : December 19, 2024. … WebApr 5, 2024 · Beyond FLAME, Inari continues to invest heavily in its robust clinical study pipeline. Positive long-term late-breaking results were recently presented at the American Venous Forum annual meeting ... iowa dot bridge law chart
Inari Medical’s FlowTriever System Studied in FLAME Trial for …
WebMar 5, 2024 · FLAME study results . Results revealed that the primary endpoint occurred in 17.0% of FT arm patients, a significantly lower rate than the performance goal of 32.0% (P = 0.017), and in 63.9% of context arm patients (P = 0.999). ... The study was sponsored by Inari Medical, the manufacturer of the FlowTriever device. Open; Explore the Site ... WebMar 6, 2024 · Image courtesy of Inari Medical via YouTube (see article below for video) Inari Medical presented an interim analysis Sunday at ACC.23 from the FLAME study (scroll down for the key findings), evaluating outcomes in patients with high risk, massive PE treated with the FlowTriever (see video below). The primary outcomes measure is a … WebMar 6, 2024 · /EIN News/ -- IRVINE, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced positive results from the FLAME study in high-risk/massive pulmonary embolism (“PE”). opal atc